Cero Therapeutics Holdings Stock Return On Asset
| CEROW Stock | 0.02 0.0007 4.86% |
CERo Therapeutics Holdings fundamentals help investors to digest information that contributes to CERo Therapeutics' financial success or failures. It also enables traders to predict the movement of CERo Stock. The fundamental analysis module provides a way to measure CERo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CERo Therapeutics stock.
Return On Assets is likely to drop to -0.0003 in 2025. CERo | Return On Asset |
CERo Therapeutics Holdings Company Return On Asset Analysis
CERo Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current CERo Therapeutics Return On Asset | -0.45 |
Most of CERo Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CERo Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CERo Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for CERo Therapeutics is extremely important. It helps to project a fair market value of CERo Stock properly, considering its historical fundamentals such as Return On Asset. Since CERo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CERo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CERo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
CERo Total Assets
Total Assets |
|
Based on the latest financial disclosure, CERo Therapeutics Holdings has a Return On Asset of -0.4528. This is 94.83% lower than that of the Healthcare sector and 98.08% lower than that of the Biotechnology industry. The return on asset for all United States stocks is notably higher than that of the company.
CERo Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CERo Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CERo Therapeutics could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics of similar companies.CERo Therapeutics is currently under evaluation in return on asset category among its peers.
CERo Fundamentals
| Return On Asset | -0.45 | ||||
| Number Of Shares Shorted | 25.46 K | ||||
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | (2.27) X | ||||
| Cash Flow From Operations | (1.52 K) | ||||
| Beta | -0.46 | ||||
| Total Asset | 8.56 M | ||||
| Retained Earnings | (14.2 M) | ||||
| Working Capital | 5.91 M | ||||
| Net Asset | 8.56 M |
About CERo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CERo Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CERo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CERo Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.